Recent Finacing
Recent Raise
Fibrotech Therapeutics develops proprietary small-molecule tranilast analogues as orally bioavailable antifibrotic drugs, advancing lead candidate FT011 for diabetic nephropathy and broader fibrotic/inflammatory indications.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors